



HHS Public Access

Author manuscript

Biochemistry. Author manuscript; available in PMC 2015 July 08.

Published in final edited form as:

Biochemistry. 2010 November 30; 49(47): 10137–10145. doi:10.1021/bi101700e.

MASS SPECTROMETRIC IDENTIFICATION OF PHOSPHORYLATION SITES IN GUANYLYL CYCLASE A AND B†

Andrea R. Yoder¹, Matthew D. Stone², Timothy J. Griffin², and Lincoln R. Potter^{1,2,*}

¹Department of Pharmacology, University of Minnesota, Minneapolis MN 55455

²Department of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, Minneapolis MN 55455

Abstract

Guanylyl cyclase A and B (GC-A and GC-B) are transmembrane guanylyl cyclase receptors that mediate the physiologic effects of natriuretic peptides. Some sites of phosphorylation are known for rat GC-A and GC-B, but no phosphorylation site information is available for the human homologs. Here, we used mass spectrometry to identify phosphorylation sites in GC-A and GC-B from both species. Tryptic digests of receptors purified from HEK293 cells were separated and analyzed by nLC-MS-MS. Seven sites of phosphorylation were identified in rat GC-A (S497, T500, S502, S506, S510, T513, and S487) and all of these sites except S510 and T513 were observed in human GC-A. Six phosphorylation sites were identified in rat GC-B (S513, T516, S518, S523, S526, and T529) and all six sites were also identified in human GC-B. Five sites are identical between GC-A and GC-B. S487 in GC-A and T529 in GC-B are novel, uncharacterized sites. Substitution of alanine for S487 did not affect initial ligand-dependent GC-A activity, but a glutamate substitution reduced activity 20%. Similar levels of ANP-dependent desensitization were observed for the wild type, S487A and S487E forms of GC-A. Substitution of glutamate or alanine for T529 increased or decreased ligand-dependent cyclase activity of GC-B, respectively, and T529E increased cyclase activity in a GC-B mutant containing glutamates for all five previously identified sites as well. In conclusion, we identified and characterized new phosphorylation sites in GC-A and GC-B and provide the first evidence of phosphorylation sites within human guanylyl cyclases.

Natriuretic peptides are pleiotropic factors that regulate blood pressure, cardiac hypertrophy, long bone growth and other functions (1). Atrial natriuretic peptide (ANP) and B-type natriuretic peptide (BNP) are released from the heart in response to cardiac chamber stretch. Both peptides reduce cardiac stress by decreasing blood pressure and cardiac hypertrophy. C-type natriuretic peptide (CNP) is found in bone, endothelium and neuronal tissues. It

†This work was supported by NIH grant R21HL0934402 to LRP.

*To whom correspondence should be addressed: 321 Church St SE, 6-155 Jackson Hall, Minneapolis, MN 55455, Tel: 612-624-7251, Fax: 612-624-7282, potter@umn.edu.

SUPPORTING INFORMATION AVAILABLE

A supplemental figure demonstrating the specificity of the antibodies used for immunoprecipitation is available as supporting information (Figure S1). Also included are larger, more detailed versions of all MS/MS spectra presented here (Figures S2–S16). Additionally, each spectrum is accompanied by a detailed b- and y-ion fragmentation table highlighting matched fragments. This material is available free of charge via the Internet at <http://pubs.acs.org>.

stimulates long bone growth, axonal pathfinding and vasorelaxation. The signaling receptor for ANP and BNP is guanylyl cyclase-A (GC-A), also known as natriuretic peptide receptor-A, and the signaling receptor for CNP is guanylyl cyclase-B (GC-B), also known as natriuretic peptide receptor-B. Both GC-A and GC-B are transmembrane guanylyl cyclases that catalyze the synthesis of cGMP upon ligand binding (2).

In contrast to most cell surface receptors, GC-A and GC-B are basally phosphorylated and are desensitized by dephosphorylation (3–7). Upon exposure to ligand, the receptors are initially activated, but prolonged ligand exposure causes concomitant dephosphorylation and desensitization (6). Initial metabolically labeling studies identified six phosphorylation sites in rat GC-A (S497, T500, S502, S506, S510, and T513) and five phosphorylation sites in rat GC-B (S513, T516, S518, S523, and S526) (8, 9). Importantly, all of these phosphorylation sites were shown to regulate enzymatic activity because the mutation of any single residue to alanine reduced receptor phosphate content and natriuretic-dependent guanylyl cyclase activity without affecting protein levels or detergent-dependent guanylyl cyclase activity (7). Furthermore, mutation of multiple residues to alanine resulted in receptors that bound hormone but could not be activated (7, 8). In contrast, conversion of some residues to glutamate in GC-A yielded a hormonally responsive receptor that was resistant to short-term desensitization (10).

Although the initial tryptic phosphopeptide mapping experiments identified several phosphorylation sites, we believe that additional sites remain to be discovered because highly homologous sea urchin guanylyl cyclases contain 15 – 17 moles of phosphate/receptor (11) whereas only five or six sites have been previously identified in GC-B and GC-A, respectively. Mass spectrometry provides direct chemical evidence of phosphorylation sites, which has never been demonstrated for GC-A or GC-B. Here, we used mass spectrometry to identify and characterize two new phosphorylation sites, chemically confirm previous identified sites, and identify phosphorylated residues in human natriuretic peptide receptors for the first time.

EXPERIMENTAL PROCEDURES

Reagents

PhosSelect affinity gel for immobilized metal affinity chromatography (IMAC), trypsin and rat ANP were purchased from Sigma-Aldrich (St. Louis, MO), Empore SDB-XC discs were from 3M Corp (St. Paul, MN).

Cell Lines

Human embryonic kidney 293 cells stably overexpressing rat or human GC-A or GC-B were maintained as previously described (12, 13). Transient transfections were performed in cells that lack endogenous expression of any natriuretic peptide receptors (293neo cells) as previously described (12, 13).

Immunoprecipitation

Natriuretic peptide receptors were immunoprecipitated from cells stably overexpressing the desired receptor with antibodies that recognize the carboxyl-terminal of GC-A or GC-B as previously described (14, 15). Proteins were separated on Criterion gels by SDS-PAGE and visualized by Coomassie staining.

In-gel digestion

Protein bands of interest were excised from gels and digested with trypsin as described (16). Briefly, the excised band was cut into small pieces, dehydrated with acetonitrile (ACN), and treated with 1 mM DTT at 56° C for 20 min to assure reduction of cysteine residues. After another round of dehydration, samples were treated with 55 mM iodoacetamide in 100 mM NH₄HCO₃ to alkylate cysteine residues. The gel slices were again dehydrated with ACN and then rehydrated in a solution containing 12.5 ng/μL of sequence-grade trypsin in 10 mM NH₄HCO₃ on ice for 2 h before incubation at 37°C overnight. The tryptic peptides were then extracted from the gel with 1:2 solution of 5% formic acid:ACN in a two-fold excess to the trypsin solution already present. After incubating at 37°C for 30 min with shaking, the supernatant was then removed and dried by vacuum centrifugation.

Peptide methylation

Methylation of free carboxyl groups was accomplished as follows (17). Forty μL of acetyl chloride was added drop-wise to 1 mL of anhydrous methanol and then used to resuspend the dried tryptic peptide sample. The mixture was then sonicated for 1 h at room temperature and allowed to further react for 30 min at room temperature before drying by vacuum centrifugation.

Phosphopeptide enrichment and sample desalting

Immobilized metal-affinity chromatography (IMAC) was used for phosphopeptide enrichment as described (18). Briefly, tryptic peptide samples were dissolved in 100 μL IMAC binding buffer (40% ACN in 25 mM formic acid) and added to 10 μL of IMAC resin. The sample was incubated at room temperature with vigorous shaking for 1 h. The beads were then added to an equilibrated StageTip column (19) containing two 16-gauge needle punches of Empore SDB-XC discs. The IMAC resin was then washed with binding buffer to remove any non-specifically bound peptides. Peptides specifically bound to the IMAC resin were eluted onto the Empore discs with excess K₂HPO₃, pH 7. Samples were then desalted and the desired peptide fraction was eluted with 95% ACN in 0.1% trifluoacetic acid (TFA). Samples not enriched by IMAC were similarly desalted with StageTips. Sample eluates were dried by vacuum centrifugation.

Liquid Chromatography and Nanospray Mass Spectrometry

Liquid chromatography and mass spectrometry was performed essentially as described by Bandhakavi et al. (20) using an Eksigent 1DLC nanoHPLC in-line with an LTQ-Orbitrap XL (ThermoScientific) with a few exceptions. The gradient was 2–40% ACN in 0.1% formic acid over 60 min with a constant flow of 250 nL/min. Spray voltage was set to 1.95 kV, the heated capillary was set at 160 °C, and the tube lens voltage was set to either 145 V

or 65 V (the lower value was used to limit any potential phosphate loss). Full scans were performed in the orbital trap over a range of m/z 360–1800. Tandem mass spectra were scanned from the linear ion trap using collision-induced dissociation with a normalized collision energy of 35%, an isolation width of 2.0 m/z , and target values of 10,000 ions or 100 ms. A parent mass list was incorporated containing m/z values of candidate phosphopeptides with +2, +3, and +4 ionization states. The five most intense ions were selected for fragmentation. If a specific parent was not detected, the most intense ions not on the parent mass list were selected as a default. Dynamic exclusion was set for 20 s using the maximum of 500 entries and a mass window of -0.6 to 1.2 amu.

Mutagenesis

Site-directed mutagenesis of rat GC-A and GC-B was accomplished using the QuickChange II system (Stratagene, Cedar Creek, TX) as previously described (7). All mutations were confirmed by DNA sequencing.

Guanylyl cyclase assays

Crude membranes were prepared as described (21). Guanylyl cyclase assays were performed at 37°C for 5 min in a buffer containing 25 mM Hepes pH 7.4, 50 mM NaCl, 0.1% BSA, 0.5 mM 1-methyl-3-isobutylxanthine, 1 mM GTP, 0.5 μM microcystin, 1 mM EDTA, and 1–2 μCi of [α - ^{32}P]GTP, with either 5 mM MgCl_2 , 1 mM ATP, and 10 nM or 1 μM natriuretic peptide or 1% Triton X-100 with 5mM MnCl_2 being substituted for the MgCl_2 . Reactions were started by the addition of 80 μl of the above reagents to 50–200 μg of crude membrane protein suspended in 20 μl of phosphatase inhibitor buffer. Reactions were stopped by the addition of 0.5 ml 110 mM ZnOAc and 0.5 ml 110 mM NaCO_3 on ice. ^{32}P -cGMP was purified and detected as described previously (22).

Homologous desensitization assay

Cells expressing the desired receptor were incubated at 37°C for 1 hour in the presence or absence of either 100 nM or 1 μM ANP in DMEM. Cells were then washed twice with ice-cold PBS and then membranes were prepared and assayed for guanylyl cyclase activity as described above.

Data analysis

MS data were searched using the Proteome Discoverer 1.0 software pipeline using SEQUEST (ThermoScientific). Monoisotopic precursor and fragment ion tolerances were set to 10 ppm and 0.8 amu respectively. Dynamic modifications of oxidation of Met and phosphorylation of Ser and Thr and the static modification of carbamidomethylation of Cys were selected. The databases used for searching were the rat international protein index (IPI) 20081024 v3.50 (40,359 entries) or NCBI human v200806 (38,126 entries). The SEQUEST discriminant score (XCORR) and precursor mass error (ΔM) values reported here were determined by the software package. Numbering of sites of phosphorylation in human receptors is based on numbering of previously identified sites in the rat homologs.

Statistical analysis

Statistical analysis of the guanylyl cyclase data was performed with GraphPad Prism software. All p-values were obtained using an unpaired t-test where 0.05 was considered significant.

RESULTS

Identification of known phosphorylation sites in rat and human GC-A and GC-B

Rat and human forms of GC-A and GC-B were purified from HEK 293 cells by sequential immunoprecipitation-SDS-PAGE fractionation (Figure S1). Gel slices containing the receptor of interest were then subjected to in-gel tryptic digestion and resulting peptides were extracted. In some experiments, free carboxylic acid groups in the peptides were methylated and/or the phosphopeptides were enriched by immobilized metal affinity chromatography (IMAC). The peptide mixtures were then submitted to nLC-MS-MS and the resulting mass/charge data was searched against the appropriate IPI rat or NCBI human database. In the database analysis of GC-A and GC-B phosphopeptides, the peptide species noted at the top of the spectra indicate the best possible match from all possible theoretical tryptic peptides in the entire rat or human protein database of 40,359 or 38,126 proteins, respectively. In other words, when no constraints were set upon the system, the search algorithms determined that the best match for the spectrum was a specific phosphorylated peptide from GC-A or GC-B. In addition, all sites of modification were confirmed by manual inspection of MS/MS spectra.

All six previously identified phosphorylation sites in rat GC-A (9) were identified by mass spectrometry. Due to the fact that GC-A contains 6 known sites within a 17 amino acid span, peptides containing multiple phosphorylated residues were observed. Figures 1A and B illustrate MS/MS spectra consistent with the triply phosphorylated peptides SAGpSRLpTLpSGR and GpSNYGpSLLpTTmEGQFQVFAmK, respectively, where lowercase letters indicate a modification to the amino acid which they precede (p = phosphorylation; m = methylation; o = oxidation). Please note that that b-series ions and y-series ions from the MS/MS analysis are depicted as red or blue peaks, respectively, and that larger, more detailed, spectra are shown in supplemental figures. The first peptide contains a missed trypsin cleavage site, which often results when a phosphothreonine or phosphoserine is two residues C-terminal to an arginine or lysine (7). Green peaks indicate additional matches to the theoretical fragmentation pattern. XCorr and M values, as determined by the Proteome Discoverer software, are listed on each spectrum. Xcorr is the score for the match with higher values indicating a greater likelihood that the peak is the predicted peptide. M reflects the accuracy of the peptide mass measurement with lower values indicating a more precise measurement. Asterisks indicate key ions that determine which residues in the phosphopeptides are actually phosphorylated. For instance in Figure 1A, the presence of the b2 and y9 ions indicates a triply phosphorylated peptide containing phosphates likely on S497, T500, and S502. Likewise, in Figure 1B the concurrent presence of the y10, y16, b9, and y14 ions indicate phosphorylation occurs at S506, S510, and T513. Together, these two phosphopeptides contain all six known rat GC-A phosphorylation sites (S497, T500, S502, S506, S510 and T513). Spectra describing mono and diphosphorylated

versions of these peptides were observed as well but are not presented due to space limitations.

MS/MS analysis of tryptic digestions of human GC-A revealed mass/charge species corresponding to the diphosphorylated peptides SAGpSRLpTLsGR (Figure 1C) and SAGpSRLTLpSGmR (Figure 1D). The presence of the y4 and y8 ions in Figure 1C in conjunction with the presence of b7 indicate phosphorylation at S497 and T500 in this peptide. In Figure 1D, presence of the b2, b4, and y3 ions suggest phosphorylation at S497 and S502. The monophosphorylated peptide GpSNYGsLLTTEGQFQVFAK was also identified (Figure 1E), where the presence of the b5 ion in conjunction with the y17 ion indicates phosphorylation at S506. We did not observe peptides containing phosphorylated versions of S510 or T513 in human GC-A. However, the corresponding nonphosphorylated versions of these peptides also were not found when omitting the phosphopeptide enrichment step, suggesting that lack of identification may result from inability to detect the relevant peptides by mass spectrometry. Thus, for the first time, we determined that human GC-A is phosphorylated on residues corresponding to S497, T500, S502 and S506 in rat GC-A.

MS/MS analysis of proteolytic samples of rat GC-B identified all five previously known phosphorylation sites. Figure 2A illustrates a spectrum depicting the phosphopeptide GAGpSRLpTLsLR. The presence of both the y3 and b7 ions confirms phosphorylation at S513 and T516. The singly phosphorylated peptide LTLpSLR (Figure 2C) was phosphorylated on S518 as indicated by the presence of the y4 ion. Figure 2E depicts the spectrum of GSpSYGpSLoMTAHGK, which is phosphorylated at both S523 and S526, as indicated by the presence of the y11, y10, and y7 ions. These three phosphopeptides account for all previously known rat GC-B phosphorylation sites (S513, T516, S518, S523, and S526).

MS/MS analysis of tryptic digests of human GC-B revealed the phosphopeptides GAGpSRLpTLsLR (Figure 2B), LTLpSLR (Figure 2D) and GSpSYGpSLoMTAHGK (Figure 2E). In Figure 2B, the presence of the y4 and b7 ions indicates phosphorylation at S513 and T516. The presence of the y4 ion in Figure 2D suggests phosphorylation at S518. As can be seen in Figure 2F, the presence of the y11, y10, y7, b5 and y8 ions are consistent with phosphorylation at S523 and S526. Thus, for the first time, we have shown that human GC-B is phosphorylated on sites corresponding to S513, T516, S518, S523, and S526 in rat GC-B.

Identification of novel phosphorylation sites in rat and human GC-A

A novel phosphorylation site at S487 was also identified in GC-A. MS/MS spectra containing peaks corresponding to the mass/charge ratio of the peptides WEDLQPSpSLER and WEDVEPSpSLER were identified in proteolytic digest of rat and human GC-A, respectively (Figures 3A and B). In both spectra, the presence of the b7 and y4 ions indicates phosphorylation at S487. To investigate the function of this phosphorylation site, we created mutants expressing an alanine or glutamate at position 487 in rat GC-A. One micromolar ANP stimulated the guanylyl cyclase activity of GC-A to 72, 66 and 61% of the activity measured in the presence of 1% Triton X-100 and Mn²⁺GTP in membranes from

cells transfected with wild type, S487A and S487E GC-A constructs, respectively (Figure 3C). The 20% reduction in the S487E compared to wild type GC-A was statistically significant.

The effect of S487 phosphorylation on ANP-dependent desensitization of GC-A was investigated by incubating 293 cells expressing wild type or S487 mutants with ANP for 1 hour at 37°C prior to membrane preparation. ANP-dependent and detergent-dependent guanylyl activities in the resulting membranes were then determined and expressed as ratios of ANP-dependent activity/detergent-dependent activity to control for transfection efficiencies and expression levels. Relative desensitization was determined by expressing cyclase activities measured in membranes from ANP exposed cells as a percentage of activities measured in membranes from cells not exposed to ANP. Prior exposure to 1 μM ANP reduced hormone-dependent cyclase activity by 52, 48 and 62% in membranes from cells expressing wild type, S487A and S487E versions of GC-A (Figure 3D). The reductions in activity were not significantly different from one another at $p < 0.05$.

Whole cell desensitization with ten-fold less ANP (100 nM) yielded similar results. Cyclase activities measured in the presence of 1 μM ANP were reduced by 50, 51, and 27% in membranes from cells expressing wild-type, S487A, and S487E versions of GC-A (Figure 3E). The amount of desensitization seen in GC-A S487E was statistically less than that of wild-type GC-A or GC-A S487A ($p = 0.008$ and $p = 0.016$, respectively). Reductions in hormone-dependent cyclase activity determined in the presence of 10 nM ANP were 48, 45, and 23% in membranes from cells expressing wild-type, S487A, and S487E versions of GC-A, respectively, and were not significantly different from one another.

Identification of a novel phosphorylation site in rat and human GC-B

In addition to the five previously identified phosphorylation sites of GC-B, our mass spectrometric analysis indicated that GC-B was also phosphorylated at T529. Peaks representing the singly and doubly phosphopeptides GSSYGSLoMpTAHGK and GSpSYGSLoMpTAHGK were observed in spectra from tryptic digests of rat and human GC-B, respectively (Figures 4A and 4B). In Figure 4A, the presence of the b7 and y6 ions indicates phosphorylation of the T529 residue. In Figure 4B, the presence of the y11 and y10 ions in conjunction with the b3 and y5 ions is consistent with phosphorylation at S523 and T529.

T529 in GC-B is homologous to T513 in GC-A, which is a known phosphorylation site (Figure 5B). To investigate the functional consequence of phosphorylation at T529, we mutated T529 in wild type rat GC-B to alanine or glutamate and measured CNP-dependent guanylyl cyclase activity in membranes from cells transiently expressing each receptor. The alanine, but not the glutamate, mutation decreased hormone-dependent cyclase activity (Figure 4C). In addition, the T529E mutation was introduced into a receptor containing glutamate substitutions at all five previously identified phosphorylation sites (GC-B-5E) (23, 24) to generate a receptor containing six glutamates (GC-B-6E). CNP-dependent guanylyl cyclase activity was significantly higher in membranes from cells expressing GC-B-6E compared to cells expressing GC-B-5E (Figure 4D). Together, these data indicate that

phosphorylation of threonine 529 is required for maximum CNP-dependent guanylyl cyclase activity of GC-B.

DISCUSSION

The veracity of these phosphopeptide identifications is supported in two ways. First, the MS/MS spectra matched to phosphopeptides from GC-A or GC-B that were obtained by searching against databases containing approximately 40,000 protein sequences, so the probability of these MS/MS peaks randomly matching the expected proteins is absurdly low. Secondly, regarding the issue of determining the exact site or sites of modification, we manually evaluated the MS/MS spectra from each phosphopeptide, and in all cases, we confirmed that the sites of phosphorylation determined by sequence database searching were supported by the peptide fragmentation pattern. Thus, the modification sites presented are well supported by the mass spectrometry data.

As a result of these methods, a total of seven phosphorylation sites within rat GC-A and six phosphorylation sites in rat GC-B were identified. A summary of known GC-A and GC-B phosphorylation sites and how they were detected is shown in Figure 5A. Of the GC-A sites, five were found in both the rat and human forms. Of the GC-B sites, all six were found in both rat and human forms. Five of the GC-B phosphorylation sites are conserved in GC-A. Mass spectrometric evidence was obtained for all sites that were originally identified by tryptic phosphopeptide mapping of ^{32}P -labeled receptors (7, 8). In addition, evidence for one new site in GC-A (S487) and one new site in GC-B (T529) was obtained. The amino acid corresponding to S487 in GC-A is an asparagine in GC-B; thus phosphorylation of S487 is unique to GC-A.

During the course of our studies, Schroter and colleagues published a report documenting phosphorylation sites in FLAG-tagged rat GC-A using mass spectroscopy techniques (25). In agreement with the information presented here, they detected phosphorylation at S487, S497, T500, S502, S506, S510, and T513 of rat GC-A overexpressed in 293 cells. They also detected phosphorylation of S487, S497 and T500 in primary endothelial cells, which is impressive given the low levels of GC-A expression in these cells. They did not analyze sites in human GC-A or any form of GC-B. Consistent with our data, they observed less ANP-dependent cyclase activity in membranes from cells expressing GC-A-S487E compared to the wild type receptor. However, they observed a 35% decrease whereas we saw a 20% decrease. Schroter and colleagues did not measure desensitization of the S487A receptor. We do not know the reason for the difference in scale of the decrease observed by the two groups but we note that ANP was present a ten-fold higher concentration in our guanylyl cyclase assay.

One major assertion of Schroter and coworkers was that phosphorylation of S487 is necessary for the homologous desensitization of rat GC-A. In fact, it was suggested to directly cause the decrease in activity seen in response to pretreatment with ligand. This conclusion was based on two major findings. First, they found that activity of the glutamate mutant was not blunted in response to 1 hr pretreatment with 100 nM ANP. Secondly, they found that the relative ratio of tryptic phosphorylated to dephosphorylated peptides

containing S487 increased approximately 9.5-fold upon ANP pretreatment as determined by semiquantitative mass spectrometry. However, the hypothesis that phosphorylation of S487 is required for homologous desensitization of GC-A is in direct conflict with our data demonstrating that S487A and S487E mutant receptors desensitize similarly to the wild type receptor (Figure 3D).

One difference between our studies and those of Schroter and colleagues is the concentration of ligand used for homologous desensitization studies. In our protocol, cells are pretreated and assayed for guanylyl cyclase activity with a maximally-stimulating concentration of ANP (1 μ M). Schroter and coworkers pretreated cells with 100 nM ANP and assayed activities in the presence of 10 nM ANP, which can be problematic due to ANP carryover from whole cell exposure. To determine if the unique desensitization protocols explain the differing results, we investigated homologous desensitization using conditions described by Schroter et al. (Figure 3E). Reductions in ANP-dependent cyclase activities were observed with wild-type as well as S487A and S487E versions of GC-A when stimulated with 10 nM or 1 μ M ANP. In all assays, S487E desensitized less than the wild type or S487A receptor, and in studies involving pretreatment with 100 nM ANP and assaying with 1 μ M ANP, these differences were significant. Regardless, we observed homologous desensitization of both the S487A and S487E GC-A using our original homologous desensitization protocol as well as the protocol described by Schroter et al., and therefore, conclude that phosphorylation of S487 is not required for homologous desensitization of GC-A.

It is clear that phosphorylation of S487 in GC-A does not have the same effect on cyclase activity as the previously identified sites. The small magnitude of the changes seen with these mutants decreases confidence that phosphorylation of S487 regulates GC-A guanylyl cyclase activity. Whether the *in vivo* regulatory effect of phosphorylation of S487 is to modulate cyclase activity or some other function is not known at the moment, but the marginal effect on cyclase activity is suggestive of other functions.

Recent studies by Bereta et al, have demonstrated phosphorylation at four serine residues within the kinase homology domain of guanylyl cyclase 1 (GC1) (also known as GC-E) from mouse retina using mass spectrometry (26). Interestingly, the four phosphorylation sites identified within the kinase homology domain of GC1 align with the highly phosphorylated region of the kinase homology domains of GC-A and GC-B. In fact, two of the GC1 phosphorylation sites (S530 and S533) align exactly with the phosphorylation sites in GC-A/B reported here (S497/513 and T500/516) (Figure 5B). However, unlike the phosphorylation sites in the same region of GC-A and GC-B, mutation of the phosphorylation sites in GC1 to either alanine or glutamic acid has no effect on guanylyl cyclase activity. Thus, other members of the guanylyl cyclase family have phosphorylation sites that do not greatly affect cyclase activity, which is similar to what we observed regarding S487 in GC-A.

Finally, it is unclear whether additional sites of phosphorylation sites remain to be determined in GC-A and GC-B. Although mass spectrometry is a very sensitive and accurate technique, if the phosphopeptides do not enter the instrument, they will not be identified. Previous studies with 32 P-labeled peptides indicated that most of the radioactivity

(~90%) was lost in the preparation procedure (9). In the current study, we have no way of measuring phosphopeptide loss since the initial protein was not labeled. In addition, some peptides ionize poorly for unknown reasons, and therefore will not be detected. Thus, we are confident in the positive identification of current sites but cannot exclude the possibility that additional phosphorylation sites remain to be determined.

In conclusion, we have identified 7 phosphorylation sites (S487, S497, T500, S502, S506, S510, and T513) in rat GC-A and 5 phosphorylation sites (S487, S497, T500, S502, and S506) in human GC-A by mass spectrometry. Six identical phosphorylated residues (S513, T516, S518, S523, S526, and T529) were biochemically identified in rat and human GC-B. These studies lay the foundation for future analysis of phosphorylation-dependent regulation of rat and human guanylyl cyclase receptors.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

ACKNOWLEDGMENTS

We thank the Center for Mass Spectrometry and Proteomics facility at the University of Minnesota for instrumentation support and the Minnesota Supercomputing Institute for computational hardware and software support.

ABBREVIATIONS

ANP	atrial natriuretic peptide
BNP	B-type natriuretic peptide
CNP	C-type natriuretic peptide
GC-A	guanylyl cyclase A
GC-B	guanylyl cyclase B
IMAC	immobilized metal affinity chromatography

REFERENCES

1. Potter LR, Yoder AR, Flora DR, Antos LK, Dickey DM. Natriuretic peptides: their structures, receptors, physiologic functions and therapeutic applications. *Handb Exp Pharmacol.* 2009;341–366. [PubMed: 19089336]
2. Potter, LR. Guanylyl Cyclases. In: Bradshaw, RA.; Dennis, EA., editors. *Handbook of Cell Signaling.* Oxford: Academic Press; 2009.
3. Potter LR. Phosphorylation-dependent regulation of the guanylyl cyclase-linked natriuretic peptide receptor B: dephosphorylation is a mechanism of desensitization. *Biochemistry.* 1998; 37:2422–2429. [PubMed: 9485390]
4. Joubert S, Labrecque J, De Lean A. Reduced activity of the NPR-A kinase triggers dephosphorylation and homologous desensitization of the receptor. *Biochemistry.* 2001; 40:11096–11105. [PubMed: 11551207]
5. Koller KJ, Lipari MT, Goeddel DV. Proper glycosylation and phosphorylation of the type A natriuretic peptide receptor are required for hormonestimulated guanylyl cyclase activity. *J Biol Chem.* 1993; 268:5997–6003. [PubMed: 8095500]

6. Potter LR, Garbers DL. Dephosphorylation of the guanylyl cyclase-A receptor causes desensitization. *J Biol Chem.* 1992; 267:14531–14534. [PubMed: 1353076]
7. Potter LR, Hunter T. Phosphorylation of the kinase homology domain is essential for activation of the A-type natriuretic peptide receptor. *Mol Cell Biol.* 1998; 18:2164–2172. [PubMed: 9528788]
8. Potter LR, Hunter T. Identification and characterization of the major phosphorylation sites of the B-type natriuretic peptide receptor. *J Biol Chem.* 1998; 273:15533–15539. [PubMed: 9624142]
9. Potter LR, Hunter T. Identification and characterization of the phosphorylation sites of the guanylyl cyclase-linked natriuretic peptide receptors A and B. *Methods.* 1999; 19:506–520. [PubMed: 10581150]
10. Potter LR, Hunter T. A constitutively "Phosphorylated" guanylyl cyclase-linked atrial natriuretic peptide receptor mutant is resistant to desensitization. *Mol Biol Cell.* 1999; 10:1811–1820. [PubMed: 10359598]
11. Ramarao CS, Garbers DL. Purification and properties of the phosphorylated form of guanylate cyclase. *J Biol Chem.* 1988; 263:1524–1529. [PubMed: 2891712]
12. Dickey DM, Burnett JC Jr, Potter LR. Novel bifunctional natriuretic peptides as potential therapeutics. *J Biol Chem.* 2008; 283:35003–35009. [PubMed: 18940797]
13. Dickey DM, Yoder AR, Potter LR. A familial mutation renders atrial natriuretic Peptide resistant to proteolytic degradation. *J Biol Chem.* 2009; 284:19196–19202. [PubMed: 19458086]
14. Bryan PM, Potter LR. The atrial natriuretic peptide receptor (NPR-A/GC-A) is dephosphorylated by distinct microcystin-sensitive and magnesium-dependent protein phosphatases. *J Biol Chem.* 2002; 277:16041–16047. [PubMed: 11821394]
15. Abbey SE, Potter LR. Vasopressin-dependent inhibition of the C-type natriuretic peptide receptor, NPR-B/GC-B, requires elevated intracellular calcium concentrations. *J Biol Chem.* 2002; 277:42423–42430. [PubMed: 12196532]
16. Shevchenko A, Tomas H, Havlis J, Olsen JV, Mann M. In-gel digestion for mass spectrometric characterization of proteins and proteomes. *Nat Protoc.* 2006; 1:2856–2860. [PubMed: 17406544]
17. Ficarro SB, Salomon AR, Brill LM, Mason DE, Stettler-Gill M, Brock A, Peters EC. Automated immobilized metal affinity chromatography/nano-liquid chromatography/electrospray ionization mass spectrometry platform for profiling protein phosphorylation sites. *Rapid Commun Mass Spectrom.* 2005; 19:57–71. [PubMed: 15570572]
18. Villen J, Gygi SP. The SCX/IMAC enrichment approach for global phosphorylation analysis by mass spectrometry. *Nat Protoc.* 2008; 3:1630–1638. [PubMed: 18833199]
19. Rappsilber J, Mann M, Ishihama Y. Protocol for micro-purification, enrichment, pre-fractionation and storage of peptides for proteomics using StageTips. *Nat Protoc.* 2007; 2:1896–1906. [PubMed: 17703201]
20. Bandhakavi S, Stone MD, Onsongo G, Van Riper SK, Griffin TJ. A dynamic range compression and three-dimensional peptide fractionation analysis platform expands proteome coverage and the diagnostic potential of whole saliva. *J Proteome Res.* 2009; 8:5590–5600. [PubMed: 19813771]
21. Antos LK, Abbey-Hosch SE, Flora DR, Potter LR. ATP-independent activation of natriuretic peptide receptors. *J Biol Chem.* 2005; 280:26928–26932. [PubMed: 15911610]
22. Bryan PM, Potter LR. The atrial natriuretic peptide receptor (NPR-A/GC-A) is dephosphorylated by distinct microcystin-sensitive and magnesium-dependent protein phosphatases. *J Biol Chem.* 2002; 277:16041–16047. [PubMed: 11821394]
23. Abbey-Hosch SE, Smirnov D, Potter LR. Differential regulation of NPR-B/GC-B by protein kinase c and calcium. *Biochem Pharmacol.* 2005; 70:686–694. [PubMed: 16005434]
24. Potthast R, Abbey-Hosch SE, Antos LK, Marchant JS, Kuhn M, Potter LR. Calcium-dependent dephosphorylation mediates the hyperosmotic and lysophosphatidic acid-dependent inhibition of natriuretic peptide receptor-B/guanylyl cyclase-B. *J Biol Chem.* 2004; 279:48513–48519. [PubMed: 15371450]
25. Schroter J, Zahedi RP, Hartmann M, Gassner B, Gazinski A, Waschke J, Sickmann A, Kuhn M. Homologous desensitization of guanylyl cyclase A, the receptor for atrial natriuretic peptide, is associated with a complex phosphorylation pattern. *FEBS J.* 2010; 277:2440–2453. [PubMed: 20456499]

26. Bereta G, Wang B, Kiser PD, Baehr W, Jang GF, Palczewski K. A functional kinase homology domain is essential for the activity of photoreceptor guanylate cyclase 1. *J Biol Chem.* 2010; 285:1899–1908. [PubMed: 19901021]

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript




Figure 1. Tandem mass spectrometric spectra depicting phosphorylated residues in rat GC-A and human GC-A

Receptors were purified and digested with trypsin prior to analysis by tandem mass spectrometry. Spectra for each phosphopeptide are color coded for matched b- and y-ions in red and blue, respectively. Other matches to the theoretical fragmentation are shown in green. For clarity, only selected species are labeled within the spectra. The primary amino acid sequence for each phosphorylated peptide is denoted on each spectrum and all b- and y-ions matched from the spectrum are marked. Lowercase letters directly preceding amino acids indicate modifications (p = phosphorylated; m = methylated; o = oxidized). Precursor

ion m/z value and charge state are listed for the spectrum. SEQUEST discriminant score (XCurr) and mass error (ΔM) values reported for the spectrum were determined by the Proteome Discoverer software. Asterisks indicate ions that support the phosphorylation of specific serines or threonines. (A) Tandem mass spectrum identifying pS497, pT500, and pS502 within rat GC-A. (B) Tandem mass spectrum identifying pS506, pS510, and pT513 within rat GC-A. (C) Tandem mass spectrum identifying pS497 and pT500 within human GC-A. (D) Tandem mass spectrum identifying pS497 and pS502 within human GC-A. (E) Tandem mass spectrum identifying pS506 within human GC-A.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript




Figure 2. Tandem mass spectrometric spectra depicting phosphorylated residues in rat and human GC-B

Spectra were generated and are labeled as described in Figure 1. (A) Tandem mass spectrum identifying pS513 and pT516 within rat GC-B. (B) Tandem mass spectrum identifying pS513 and pT516 within human GC-B. (C) Tandem mass spectrum identifying pS518 within rat GC-B. (D) Tandem mass spectrum identifying pS518 within human GC-B. (E) Tandem mass spectrum identifying pS523 and pT526 within rat GC-B. (F) Tandem mass spectrum identifying pS523 and pT526 within human GC-B.




Figure 3. Mass spectroscopic identification of phosphorylated Ser-487 in rat and human GC-A and functional characterization of Ser-487 in rat GC-A
 Spectra were generated and are labeled as described in Figure 1. (A) Tandem mass spectrum identifying pS487 in rat GC-A. (B) Tandem mass spectrum identifying pS487 in human GC-A. (C) Guanylyl cyclase activities in membranes of 293 cells expressing wild type or mutant forms rat GC-A where n = 25. Assays were conducted in the presence of either 1 μ M ANP or 1% Triton X-100. Results are normalized to the maximum cGMP concentrations obtained in the presence of Triton X-100. (D) Homologous desensitization assessed by guanylyl cyclase activities in 293 cells expressing wild type or mutant forms of rat GC-A

preincubated with 1 μM ANP for one hour. Assays were conducted in the presence of either 1 μM ANP or 1% Triton X-100. Results are expressed as the activation ratio of ligand-stimulated activity divided by activity determined in the presence of 1 % Triton-X 100 and Mn^{2+} GTP, which were then normalized to the non-pretreated control for each receptor where $n = 8$. (E) Homologous desensitization assessed by guanylyl cyclase activities in 293 cells expressing wild type or mutant forms of rat GC-A preincubated with 100 nM ANP for one hour. Assays were conducted in the presence of either 10 nM ANP, 1 μM ANP or 1% Triton X-100. Results are expressed as the activation ratio of ligand-stimulated activity divided by activity determined in the presence of 1 % Triton-X 100 and Mn^{2+} GTP, which were then normalized to the non-pretreated control for each receptor where $n = 6$.




Figure 4. Mass spectroscopic identification of phosphorylated Thr-529 in rat and human GC-B Spectra were generated and are labeled as described in Figure 1. (A) Tandem mass spectrum identifying pT529 in rat GC-B generated from a tryptic digest of rat GC-B. (B) Tandem mass spectrum identifying pS523 and pT529 in human GC-B. (C) Guanylyl cyclase activities from membranes obtained from 293 cells expressing rat wild type GC-B with T529 mutated to either alanine or glutamic acid where $n = 8$. (D) Guanylyl cyclase activities from membranes obtained from 293 cells expressing either rat GC-B containing glutamic acid substitutions at all five previously known phosphorylated residues (GC-B-5E) or rat GC-B with a glutamic acid residue substitution at T529 in addition to previously known sites (GC-B-6E) where $n = 4$. Cyclase activities were determined in the presence or 1 μM CNP or 1% Triton X-100. Results are normalized to the maximum cGMP concentrations obtained in the presence of Triton X-100.




Figure 5. Identified phosphorylation sites in mammalian particulate guanylyl cyclases
 (A) Schematic of the rat and human membrane-bound natriuretic peptide receptors illustrating known phosphorylated residues. Phosphorylation sites are identified both by residue number and identification procedure. BLUE residues were identified both by ³²P-phosphopeptide mapping and mass spectrometry. YELLOW residues were identified by mass spectrometry only. GREY residues are predicted to be phosphorylated by sequence homology to known phosphorylated residues. (B) Sequence alignment of phosphorylated regions from mouse (m), rat (r), and human (h) homologs of GC-A, GC-B, and retinal

guanylyl cyclase (GC-1). Positions where structurally similar residues are conserved in two or more proteins are shaded light grey. Residues conserved in all proteins are shaded in dark grey. Red residues indicate identified phosphorylation sites. Numbers on top line refer to rat GC-A sites. The alignment was performed with ClustalW.